Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a).

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
Alirocumab 1 endocrinologydiseasesdrugs
Evolocumab 1 endocrinologydiseasesdrugs
familial hypercholesterolemia 1 endocrinologydiseases
hypolipoproteinemia 1 endocrinologydiseases

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Alirocumab 4286 actionReduction of Lp(a) (%)Special notesNicotinic acidClassical drug20–30Moderate side effectsEvolocumab Alirocumab PCSK9 antibodies15–30Very low side effectsLomitapideMTP inhibitor15–32Risk of steatosisMipomersenApo
Evolocumab 4276 of actionReduction of Lp(a) (%)Special notesNicotinic acidClassical drug20–30Moderate side effects Evolocumab AlirocumabPCSK9 antibodies15–30Very low side effectsLomitapideMTP inhibitor15–32Risk of steatosisMipomersenApo
Select Disease Character Offset Disease Term Instance
familial hypercholesterolemia 2642 a positive family history of premature cardiovascular diseases, elevated Lp (a) in other family members, familial hypercholesterolemia , and in high-risk patients with a 10-year risk of fatal cardiovascular disease of 5–10% according
hypolipoproteinemia 3186 considered [[7]].End-stage renal disease and the nephrotic syndrome are most frequent causes of secondary hypolipoproteinemia (a) [[8], [9]].In many patients, an unexpected cardiovascular event induces the first measurement of

You must be authorized to submit a review.